Exvastat is an innovative, preclinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The new treatment has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as the costs of caring for these critically ill patients to health service providers.
Location: United Kingdom, England, Cambridge
Employees: 1-10
Founded date: 2016
Investors 1
| Date | Name | Website |
| 18.05.2023 | Cambridge ... | cic.vc |
Mentions in press and media 11
| Date | Title | Description |
| 21.02.2022 | Long-Term clinical outcome study of CounterCOVID patients published | Long-Term clinical outcome study of CounterCOVID patients published Lower mortality rate, better clinical status, and shorter duration of invasive ventilation were observed in hospitalised patients with COVID-19 treated with imatinib during... |
| 22.06.2021 | Exvastat: The remarkable potential of re-profiled drugs | Exvastat: The remarkable potential of re-profiled drugs Recently we learned that the use of the medication imatinib results in a 47% reduction in mortality in patients with Covid-19. Robert Tansley, our Life Sciences partner, reflects on wh... |
| 21.06.2021 | CounterCOVID study shows imatinib significantly reduces mortality by 49% in patients with COVID-19 | CounterCOVID study shows imatinib significantly reduces mortality by 49% in patients with COVID-19 Results published on Friday 18 June by Exvastat’s collaborator in The Lancet Respiratory Medicine show that oral imatinib, currently used to ... |
| 12.03.2021 | 5 top startups developing drugs for respiratory diseases | 5 top startups developing drugs for respiratory diseases Article by Start Us Insights Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the pha... |
| 27.01.2021 | A year in review: Business update January 2021 | Cambridge has always been at the forefront of innovation. As the leading venture capital investor in Cambridge, CIC plays a central role in commercialising this innovation for the benefit of society. In the last year, CIC’s existing portfol... |
| 22.06.2020 | Annual results for the year ended 31 March 2020 | Expansion to 30 portfolio companies and 46% increase in net asset value, reinforcing CIC’s position as the most active series A investor in the Cambridge ecosystem Cambridge Innovation Capital plc (CIC), the venture capital investor enablin... |
| 02.06.2020 | Exvastat Enters COVID-19 Arena With Intravenous Imatinib | Reformulating Cancer Blockbuster For ARDS by Kevin Grogan | Scrip The UK firm has tapped into EU funds through an Irish subsidiary to advance its treatment for acute respiratory distress syndrome based on a reformulation of Novartis's Gleev... |
| 18.05.2020 | Exvastat receives grant to fund clinical study of existing drug in COVID-19 treatment | Exvastat (Ireland) Ltd, a privately held biopharmaceutical company backed by Cambridge Innovation Capital, announced the Innovative Medicines Initiative has awarded the company a €3.6m grant, following its call for developers to uncover a n... |
| 18.05.2020 | Exvastat receives grant to fund clinical study of existing drug in COVID-19 treatment | Exvastat receives grant to fund clinical study of existing drug in COVID-19 treatment 18-05-2020 Exvastat (Ireland) Ltd, a privately held biopharmaceutical company backed by Cambridge Innovation Capital, announced the Innovative Medicines I... |
| 15.05.2020 | Exvastat receives prestigious Innovative Medicines Initiative grant | Exvastat receives prestigious Innovative Medicines Initiative grant to fund clinical study of imatinib in the treatment of COVID-19-associated ARDS CAMBRIDGE, UK AND DUBLIN, IRELAND - Exvastat (Ireland) Ltd, a privately held biopharmaceutic... |
Show more